A new memorandum summarizes the results of HHS-OIG’s comparison of average sales prices and average manufacturer prices for #Medicare Part B drugs during the forth quarter of 2023. Read the full memo: https://direc.to/fhvo
HHS Office of Inspector General’s Post
More Relevant Posts
-
A new memorandum summarizes the results of HHS-OIG’s comparison of average sales prices and average manufacturer prices for #Medicare Part B drugs during the first quarter of 2023. Read the full memo: https://direc.to/fgsy
To view or add a comment, sign in
-
A new memorandum summarizes the results of HHS-OIG’s comparison of average sales prices and average manufacturer prices for #Medicare Part B drugs during the second quarter of 2023. Read the full memo: https://direc.to/fgBY
To view or add a comment, sign in
-
A new memorandum summarizes the results of HHS-OIG’s comparison of average sales prices and average manufacturer prices for #Medicare Part B drugs during the third quarter of 2023. Read the full memo: https://direc.to/fhTi
To view or add a comment, sign in
-
NPC Chief Strategy Officer | Biopharmaceutical & Health Policy Researcher | Public Speaker | Kimpossibility Life Coach & Yoga Teacher
The long-awaited Medicare drug price negotiation list is out. The biggest surprise might be how many products on this list are expected to be ineligible due to anticipated generic/biosimilar competition. Reach out to me for help determine the impact of the list for you and your company. More info here: https://lnkd.in/eVz3BmJt What many of us expected to happen here: https://lnkd.in/e7PUxp5R #inflationreductionact
End of
Translation To view or add a comment, sign in -
Check out our kick-off to the next Expect More series featuring drug pricing! Do the six identified reasons for higher US drug pricing within our feature mirror what top pharmaceutical chiefs stated on Capitol Hill yesterday? #drugpricing
The question I get when people find out that I work in the pharmacy space is "why do drugs cost so much." We are going to try to explain the unique problems the US industry faces in the next couple of weeks. https://wix.to/nzKZGwG
To view or add a comment, sign in
-
"Patented, name-brand drugs cost more (i.e., are likelier to be in the 80% margin realm), while generic drugs cost less and therefore have lower margins. That would suggest hikes following price transparency are more liable to be concentrated on the cheaper generic drugs than the name-brand ones, whose already topped-out margins may need to drop." Ummmm...... Adam Fein..... help? https://lnkd.in/gVqthrjT
Frankly, CVS’s simplified drug pricing plan is more confusing than ever
fastcompany.com
To view or add a comment, sign in
-
Medicare, the country’s biggest buyer of prescription drugs, gained the authority to negotiate the price of certain high-price medicines under the Inflation Reduction Act. Lawmakers, patients and other supporters said the power was needed to arrest spiraling drug costs. In September, Medicare officials are scheduled to publish the names of 10 drugs it will start negotiating prices for next year, with the prices to go into effect in 2026. The program will gradually add additional products to its negotiation list, including 15 more drugs in 2027.
Merck Challenges U.S. Government’s New Powers to Negotiate Drug Prices
wsj.com
To view or add a comment, sign in
-
https://lnkd.in/gqph_J2r Seriously, after an award winning 483 that included indiscriminate and over enthusiastic filing in the round file, what else can the agency do to show appreciation. The sad part this is only for exports to the US, the rest of the customers continue to receive the not so fantastic efforts of this "pharma” manufacturer. Where are the homies (regulators) doing about the sales to the domestic markets? Sales to other global markets?
India's Intas gets more bad news from FDA with import alert
fiercepharma.com
To view or add a comment, sign in
-
Great first step, but clearly more work to be done when it comes to the outrageous price gouging that has run rampant in the #pharmaindustry for way too long. #CMS states that 8,247,000 people with #Medicare Part D used these 10 drugs, which accounted for $50.5B in total or about 20% of Part D gross covered prescription cost. Notable absence: #OrphanDrugs. #Humira, which is the most popular drug in the world with sales at $18.9B last year and an annual cost of $80,000. Hopefully we will see #drugs like Humira on the next round, but won't hold my breath.
To view or add a comment, sign in
46,402 followers